Update in Sjogren syndrome

Current Opinion in Rheumatology

Volumn 12, Issue 5, 2000, Pages 391-398

  Fox, Robert I ^a,c   Stern, Michael ^b   Michelson, Paul ^a  

^a SCRIPPS MEMORIAL HOSPITAL   (United States)

^b ALLERGAN INC   (United States)

^c Allergy and Rheumatology Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CEVIMELINE; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE; DEXAMETHASONE; LONGOVITAL; MUSCARINIC M3 RECEPTOR ANTAGONIST; PILOCARPINE; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; MUSCARINIC AGENT;

CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DOUBLE BLIND PROCEDURE; FATIGUE; FIBROMYALGIA; HERB; HUMAN; HUMAN TISSUE; KERATOCONJUNCTIVITIS SICCA; LABORATORY TEST; MYALGIA; PATHOGENESIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SJOEGREN SYNDROME; XEROSIS; XEROSTOMIA; ADULT; ANIMAL; BLOOD; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; FEMALE; FETUS DISTRESS; IMMUNOLOGY; PREGNANCY; SALIVA; SECRETION; SKIN DISEASE; XEROPHTHALMIA;

ADULT; ANIMALS; ANTI-INFLAMMATORY AGENTS; AUTOANTIBODIES; CARDIOVASCULAR DISEASES; CENTRAL NERVOUS SYSTEM DISEASES; DEXAMETHASONE; FEMALE; FETAL DISTRESS; HUMANS; MUSCARINIC AGONISTS; PREGNANCY; SALIVA; SJOGREN'S SYNDROME; SKIN DISEASES; XEROPHTHALMIA;

EID: 0033624630     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200009000-00007     Document Type: Review

References (108)

1. Sjogren's syndrome: A community-based study of prevalence and impact-comment on the article by Thomas et al
2. The 1998 Castroviejo Lecture. New strategies in the treatment of dry-eye states
3. Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes
4. Xerostomia: A prevalent condition in the elderly
5. Assessment of keratoconjunctivitis sicca in patients with fibromyalgia: Results of a prospective study
6. A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities I. Precision, sensitivity, and specificity
7. Cost effective use of laboratory tests in rheumatology
8. The Europian classification criteria for Sjogren's syndrome (SS): Proposal for modification of the rules for classification suggested by the analysis of the receiver operating characteristic (ROCS) curve of the criteria performance
9. Tear lysozyme activity in frozen Schirmer strips and salivary gland biopsy as parameters of lacrimal gland function
10. Familial aggregation of lupus and autoimmunity in an unusual multiplex pedigree
11. Primary Sjogren's syndrome in men: Clinical and immunological characteristics
12. Health-related quality of life in primary Sjogren's syndrome, rheumatoid arthritis and fibromyalgia compared to normal population data using SF-36
13. Dry eyes: An emerging epidemic
14. Frontal midline theta rhythm and eyeblinking activity during a VDT task and a video game: Useful tools for psychophysiology in ergonomics
15. Extrahepatic manifestations of chronic hepatitis C infection and the interrelationship between primary Sjogren's syndrome and hepatitis C in Swedish patients
16. Treatment of autoimmune and extrahepatic manifestations of hepatitis C virus infection
17. Autoimmunity and extrahepatic manifestations in hepatitis C virus infection
18. Human T-cell lymphotropic virus type 1 infection and ocular manifestations in Sac Paulo, Brazil
19. Relationship between Sjogren's syndrome and human T-lymphotropic virus type I infection: Follow-up study of 83 patients
20. Sicca syndrome and HTLV-I-associated myelopathy/tropical spastic paraparesis
21. Sjogren's syndrome (SS) in patients with human T cell leukemia virus I associated myelopathy: Paradoxical features of the major salivary glands compared to classical SS
22. Prevalence of Sjogren's-like syndrome in a cohort of HIV-1-positive patients: Descriptive pathology and immunopathology
23. Human retrovirus-5 in rheumatic disease
24. Epidemic keratoconjunctivitis outbreak at a tertiary referral eye care clinic
25. Meta-analyses of the relation between silicone breast implants and the risk of connective-tissue diseases
26. The European classification criteria for Sjogren's syndrome (SS): Proposal for modification of the rules for classification suggested by the analysis of the receiver operating characteristic (ROCS) curve of the criteria performance
27. Diseases associated with ocular surface abnormalities: The importance of reflex tearing
28. Clinical application of a homogeneous colorimetric assay for tear lysozyme
29. Sicca symptoms, saliva and tear production, and disease variables in 636 patients with rheumatoid arthritis
30. Association of meibum oleic acid with meibomian seborrhea
31. Atopic and vernal keratoconjunctivitis: A model for studying atopic disease
32. The flow rate and composition of human labial gland saliva
33. Caries and periodontal conditions in patients with primary Sjogren's syndrome
34. Oral microbial flora in Sjogren's syndrome
35. Periodontal manifestations of collagen vascular disorders
36. Lower frequency of focal lip sialadenitis (focus score) in smoking patients: Can tobacco diminish the salivary gland involvement as judged by histological examination and anti-SSA/Ro and anti-SSB/La antibodies in Sjogren's syndrome?
37. The place of magnetic resonance and ultrasonographic examinations of the parotid gland in the diagnosis and follow-up of primary Sjogren's syndrome
38. Sjogren's syndrome: Comparison of assessments with quantitative salivary gland scintigraphy and contrast sialography
39. The cutaneous pathology associated with seropositivity for antibodies to SSA (Ro): A clinicopathologic study of 23 adult patients without subacute cutaneous lupus erythematosus
40. Lymphocytic autoimmune hidradenitis, cutaneous leucocytoclastic vasculitis and primary Sjogren's syndrome
41. Microvascular abnormalities in Sjogren's syndrome: Nailfold capillaroscopy
42. Urticarial vasculitis
43. The relationship between facial annular erythema and anti-SS-A/Ro antibodies in three East Asian women
44. Air trapping in primary Sjogren syndrome correlation of expiratory CT with pulmonary function tests
45. Elevation of anti-cytokeratin 19 antibody in sera of the patients with idiopathic pulmonary fibrosis and pulmonary fibrosis associated with collagen vascular disorders
46. Parasympathetic failure does not contribute to ocular dryness in primary Sjogren's syndrome
47. Autonomic nervous system dysfunction may explain the multisystem features of fibromyalgia
48. Relationship between chronic fatigue syndrome and neurally mediated hypotension
49. Sjogren autoantibodies modify neonatal cardiac function via M1 muscarinic acetylcholine receptor activation
50. A diffuse T lymphocytic gastrointestinal mucosal infiltration associated with Sjogren's syndrome resulting in a watery diarrhea syndrome and responsive to immunosuppressive therapy
51. Acute self-limiting jejunitis as the first manifestation of microscopic polyangiitis associated with Sjogren's disease: Report of one case and review of the literature
52. Malignant lymphoma in primary Sjogren's syndrome: A multicenter, retrospective, clinical study by the European Concerted Action on Sjogren's Syndrome
53. Dry eye after haematopoietic stem cell transplantation
54. Immune-mediated inner ear disease
55. Evidence linking the 68 kilodalton antigen identified in progressive sensorineural hearing loss patient sera with heat shock protein 70
56. Neurological manifestations in Sjogren syndrome
57. Large annular purpura and paraneoplastic purpura in a patient with Sjogren's syndrome and cervical cancer
58. Cutaneous manifestations of Sjogren's syndrome associated with myasthenia gravis
59. Central nervous system involvement in Sjogren's syndrome: Evidence from neuropsychological testing and HMPAO-SPECT
60. Anxiety and depression in patients with primary Sjogren's syndrome
61. Fluctuation of anti-Ro/SS-A antibody levels in patients with systemic lupus erythematosus and Sjogren's syndrome: A prospective study
62. Isotype distribution of anti-Ro/SS.A and anti-La/SS-B antibodies in plasma and saliva of patients with Sjogren's syndrome
63. Glycosylation of immunoglobulin A influences its receptor binding
64. Ro/SS-A- and La/SS-B-reacfive B lymphocytes in peripheral blood of patients with Sjogren's syndrome
65. Immunoglobulin variable genes and epitope recognition of human monoclonal anti-Ro 52-kd in primary Sjogren's syndrome
66. Role of HLA in congenital heart block: Susceptibility alleles in mothers
67. Defining a novel 75-kDa phosphoprotein associated with SS-A/Ro and identification of distinct human autoantibodies
68. Anti-cytoplasmic autoantibodies reactive with epithelial cells of the salivary gland in sera from patients with Sjogren's syndrome: Their disease- and organ-specificities
69. The clinical relevance of antibodies to ribosomal-P common epitope in two targeted systemic lupus erythematosus populations: A large cohort of consecutive patients and patients with active central nervous system disease
70. Autoantibodies in primary Sjogren's syndrome are directed against proteasomal subunits of the alpha and beta type
71. Immunohistochemical detection of insulin-like growth factor-I in the labial salivary glands of patients with Sjogren's syndrome
72. Big prolactin 60 kDa is overexpressed in salivary glandular epithelial cells from patients with Sjogren's syndrome
73. Detection of alterations in the levels of neuropeptides and salivary gland responses in the non-obese diabetic mouse model for autoimmune sialoadenitis
74. Modulation of the immune response by the neuroendocrine axis in rheumatoid arthritis
75. Serum soluble adhesion molecules (sICAM-1, sVCAM-1, sE-selectin) and neopterin in patients with Sjogren's syndrome
76. Sjogren's syndrome and MALT lymphomas of salivary glands: A DNA-cytometric and interphase-cytogenetic study
77. Are there site specific differences among the MALT lymphomas-morphologic, clinical?
78. Impaired microvascular response to cholinergic stimuli in primary Sjogren's syndrome
79. Stimulation with carbachol alters endomembrane distribution and plasma membrane expression of intracellular proteins in lacrimal acinar cells
80. Conjunctival epithelium expression of HLA-DR in dry eye patients
81. Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjogren's syndrome keratoconjunctivitis sicca
82. Expression of CD40/CD40 ligand and Bcl-2 family proteins in labial salivary glands of patients with Sjogren's syndrome
83. Expression of B7 costimulatory molecules by salivary gland epithelial cells in patients with Sjogren's syndrome
84. Accumulation of common T cell clonotypes in the salivary glands of patients with human T lymphotropic virus type I-associated and idiopathic Sjogren's syndrome
85. Analysis of V(H)-D-J(H) gene transcripts in B cells infiltrating the salivary glands and lymph node tissues of patients with Sjogren's syndrome
86. Possible involvement of IL-12 expression by Epstein-Barr virus in Sjogren syndrome
87. Androgen influence on lacrimal gland apoptosis, necrosis, and lymphocytic infiltration
88. Estrogen deficiency accelerates autoimmune exocrinopathy in murine Sjogren's syndrome through fas-mediated apoptosis
89. Gender- and androgen-related influence on the expression of proto-oncogene and apoptotic factor mRNAs in lacrimal glands of autoimmune and non-autoimmune mice
90. T cell attractant chemokine expression initiates lacrimal gland destruction in nonobese diabetic mice
91. Current issues in the diagnosis and treatment of Sjogren's syndrome
92. New concepts for the development of autoimmune exocrinopathy derived from studies with the NOD mouse model
93. Th1 versus Th2 immune responses in autoimmune lacrimal gland disease in MRL/Mp mice
94. Treatment with anti-CD86 costimulatory molecule prevents the autoimmune lesions in murine Sjogren's syndrome (SS) through up-regulated Th2 response
95. Fas ligand-mediated exocrinopathy resembling Sjogren's syndrome in mice transgenic for IL-10
96. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome
97. Treatment of dry eye by autologous serum application in Sjogren's syndrome
98. Application of the high-risk strategy to control dental caries
99. Effects of fluoride- and chlorhexidine-containing varnishes on plaque composition and on demineralization of dentinal grooves in situ
100. Treatment of primary Sjogren's syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: A phase II clinical trial. IFN Protocol Study Group
101. Zidovudine in primary Sjogren's syndrome
102. LongoVital in the treatment of Sjogren's syndrome
103. Long-term follow-up of patients treated with acupuncture for xerostomia and the influence of additional treatment
104. Evening primrose oil and borage oil in rheumatologic conditions
105. Neurally mediated hypotension and chronic fatigue syndrome
106. Octreotide treatment of chronic intestinal pseudoobstruction secondary to connective tissue diseases
107. Anti-adhesion molecule therapy as an interventional strategy for autoimmune inflammation
108. Androgens and dry eye in Sjogren's syndrome